Matthias Alder
CIK 1370820 · Chief Executive Officer · last filed 2024-03-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SCMP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
6707 DEMOCRACY BLVD., STE. 505
BETHESDA, MD 28017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GANX | Chief Executive Officer | 21,140 | $1.19 | $25.1K | -$5.1K | 11 | 2024-03-28 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | EVP, Gen. Council & Sec. | 4,763 | — | — | -$2.40M | 11 | 2017-07-07 |
| MICROMET, INC. (MITI) Delisted | SVP, GC and Secretary | 200 | — | — | -$154.1K | 10 | 2011-03-03 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-12-28 | GANX | Grant (A) | — | $0 | EDGAR |
| 2017-07-07 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +673 | $6.0K | EDGAR |
| 2017-05-10 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +641 | $6.0K | EDGAR |
| 2017-03-08 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +33,000 | $0 | EDGAR |
| 2017-01-06 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +134 | $1.4K | EDGAR |
| 2016-11-28 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Mixed | — | -$1.15M | EDGAR |
| 2016-10-21 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +639 | $6.0K | EDGAR |
| 2016-07-18 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +752 | $7.0K | EDGAR |
| 2016-06-16 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +645 | $6.0K | EDGAR |
| 2016-03-04 | Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Grant (A) | +477 | $7.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.